Thiazolidinediones for treatment of polycystic ovary syndrome

Pharmacotherapy

Volumn 25, Issue 2, 2005, Pages 244-252

  Stout, Dena L ^a   Fugate, Susan E ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Anovulation; Insulin resistance; PCOS; Pioglitazone; Polycystic ovary syndrome; Rosiglitazone; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; CLOMIFENE; ESTROGEN; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; GONADOTROPIN; INSULIN; INSULIN SENSITIZING AGENT; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; RECOMBINANT FOLLITROPIN; ROSIGLITAZONE; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TROGLITAZONE;

ACNE; ANOVULATION; BODY MASS; CLINICAL TRIAL; DIET; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; ESTHETIC SURGERY; EXERCISE; FEMALE FERTILITY; FEMALE INFERTILITY; GLUCOSE BLOOD LEVEL; HIRSUTISM; HORMONE RESPONSE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; MEDLINE; MENSTRUAL IRREGULARITY; MENSTRUATION; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; REVIEW; SEX ROLE; UNITED STATES; WEIGHT REDUCTION;

ADULT; CHROMANS; CLINICAL TRIALS; CLOMIPHENE; CONTRACEPTIVES, ORAL; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; OVULATION; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 13544274204     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.2.244.56943     Document Type: Review

References (49)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
2. Futterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv 1999;54:403-13.
3. Franks S. Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2003;32:639-51.
4. Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician 2003;68:697-704.
5. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325-40.
6. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004;60:1-17.
7. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002;57:755-67.
8. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 2003;52:713-19.
9. O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol 1994;41:231-6.
10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
11. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
12. Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105-11.
13. Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod 1997;12(suppl 1)12:82-7.
14. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919-27.
15. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA 1982;247:1295-8.
16. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab 1989;68:966-70.
17. G.D. Searle LLC. Aldactone (spironolactone) package insert. Chicago, IL; 2003.
18. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-5.
19. Schering Corporation. Eulexin (flutamide) package insert. Kenilworth, NJ; 2003.
20. Lakryc EM, Motta EL, Soares JM, Haidar MA, de Lima GR, Baracat EC. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol 2003;17:57-63.
21. Merck & Company, Inc. Proscar (finasteride) package insert. Whitehouse Station, NJ; 2003.
22. Kurabayashi T, Kase H, Suzuki M, Sugaya S, Fujita K, Tanaka K. Endometrial abnormalities in infertile women. J Reprod Med 2003;48:455-9.
23. Ehrmann DA, Rychlik D. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med 2003;21:277-83.
24. Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002;100:665-70.
25. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3.
26. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116-23.
27. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride) package insert. Princeton, NJ; 2003.
28. Azziz R. We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome. Fertil Steril 2003;80:264-5.
29. Parulkar AA, Penderrgrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
30. Department of Health and Human Services. HHS News 2000. Rezulin to be withdrawn from the market. Available from http://www.fda.gov/bbs/topics/NEWS/ NEW00721.html. Accessed March 22, 2000.
31. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299-306.
32. Erhmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-16.
33. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related to polycystic ovary syndrome. Fertil Steril 1999;71:323-7.
34. Azziz R, Erhmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32.
35. Azziz R, Erhmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932-7.
36. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:576-80.
37. Mitwally MFM, Kuscu NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999;14:2700-3.
38. Wu XK, Zhou SY, Liu JX, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003;80:954-65.
39. Legro RS, Azziz R, Erhmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003;88:5137-44.
40. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo-and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-18.
41. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ, Chang RJ. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;88:5624-31.
42. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001;76:1057-9.
43. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004;81:624-9.
44. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003;10:99-104.
45. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-6.
46. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
47. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18(suppl):S23-9.
48. Takeda Pharmaceuticals America Inc. and Eli Lilly and Company. Actos (pioglitazone hydrochloride) package insert. Lincolnshire, IL, and Indianapolis, IN; 2003.
49. GlaxoSmithKline. Avandia (rosiglitazone maleate) package insert. Research Triangle Park, NC; 2003.